BCG

Executive Perspectives

Lessons learned from the frontline of the global COVID-19 vaccine rollout

March 2021

BCG Executive Perspectives

OBJECTIVES OF THIS DOCUMENT

COVID-19 IS A GLOBAL SOCIETAL CRISIS

We at BCG believe that the COVID-19 outbreak is first and foremost a societal crisis, threatening lives and the well-being of our global community. Society now, more than ever, needs to collaborate to protect people's lives and health, manage midterm implications, and search for lasting solutions

LEADERS NEED TO DRIVE AN INTEGRATED RESPONSE TO NAVIGATE THE CRISIS

It is the duty of health, political, societal, and business leaders to navigate through this crisis. A complex interplay of epidemic progression, societal response, government action, sector impact, and company action is playing out. This document intends to help leaders find answers and shape opinions to navigate the crisis in their own environments. It encourages thinking across the multiple time horizons over which we see the crisis manifesting itself The COVID-19 recovery will be driven by disease progression, de-averaged economic impact, government policies, and business and public responses

Flatten	Fight	Future
Typically in the initial phase after a pandemic outbreak, the goal is to urgently limit the number of new cases , especially critical care	Finding paths to collectively fight the virus, restart the economy, and support society in balancing lives and livelihood	Disease controlled through vaccine/cure/ herd immunity and treatment within sustainable medical capacities possible
Social distancing (lockdown) and partial business closures lead to economic recession with a large employment impact	Increasing economic activity with recovering GDP, some business reopenings, and social distancing on a sustainable level	Reactivated economy with strong business rebound and job growth, social restrictions limited or completely suspended
	1 Disease progression healthcare system canacity	and response
	2. Government policies and economic stimulus	
	3. Economic scenarios	
	4. Business engagement and response	
	5. Public engagement and response	

All of the above five factors result in specific economic and social outcomes in each phase

3

Epidemic Progression Global epidemic snapshot								
120M # of cases	20.7M # of active cases	2. # fata	7M ≠ of alities	35 Vaccin admin	9M e dose istere			
Month-on- month growth of new cases ²	Americas Europe Asia ³	Nov 1.7x 1.8x 1.0x	Dec 1.4x 0.8x 1.1x	Jan 1.1x 1.1x 0.7x	0.6×			



Consumer Activity Mobility							
Mobility ⁶ (month vs. Jan '20)	US Europe Japan		Nov -20% -31% -7%	Dec -20% -34% -6%	Jan -26% -47% -22%		
Domestic air travel tickets booking ^{7,8} (YoY)	US UK China		-45% -55% -5%	-43% -53% -15%	-54% -78% -37%		
Retail goods sales ⁹ (excl. auto & fuel, YoY)	US Europe ¹⁰ China		5% 0% 4%	2% 2% 4%	10% -4%		
Passenger vehicle sales ¹¹ (YoY)	US Europe China	 	-21% -5% 13%	-9% -3% 7%	-15% -22% 30%		

Business Impact Stock market performance Month end vs. 02 Jan '20 Nov Dec an S&P500 11% 15% 14% FTSE100 -18% -16% CHN SSE 10% 12% 13% Volatility Index (S&P500)¹² 1.6x 1.8x 2.7x International trade Trade value¹³ US 1% 3% 2% (YoY) 5% France 0% China 14% 13% Industrial production Purchasing US 59 57 manager's ΕU 54 55 55 index14 China 51 52 52 (base = 50)Steel production (YoY)¹⁵ 8% 6% 6%

1. Calculated as 7-day rolling average; 2. Calculated as monthly average of daily cases vs. previous month; 3. Includes Middle East and Oceania; 4. IMF Jan 2021 forecast; 5. For India, forecast is for financial year; for others, it is for calendar year YOY forecasts; stange from forecasts (where available) of Writes and Compared to Same period East and Oceania; 4. IMF Jan 2021 forecast; 5. For India, forecast is for financial year; for others, it is for calendar year YOY forecasts; ange from forecasts (where available) of Writes and Compared to Same period East and Oceania; 4. IMF Jan 2021 forecast; 5. For India, SD20 forecast; 5. For India, SD20

To be updated in forthcoming editions

4

BCG Executive Perspectives

AGENDA

GLOBAL COVID-19 VACCINE ROLLOUT

Global vaccine development and implementation

Equitable vaccine distribution and path to normality

LESSONS LEARNED FROM THE FRONTLINE OF THE

UPDATED ANALYSES AND IMPACT

Epidemic progression and virus monitoring Economic and business impact

7 key lessons learned from the frontline of the global COVID-19 vaccine rollout

2

3

2

3

Δ



INITIAL FINDINGS

Develop and implement global COVID-19 vaccination program with unprecedented speed

В

STRATEGIC PRIORITIES Minimize harm from COVID-19 and maximize equitable distribution within and across nations

Vaccine development in record time

Safe and effective vaccines were developed, tested, and approved with unprecedented speed

Vaccination uptake will follow "S-curve"

Vaccine uptake can be modeled along a predictive path, shaped by shifting constraints and supply

Vaccine effectiveness proven in real world

Israel is a successful example showing that broad vaccination across the population results in controlling cases

Developed nations must focus on uptake

Developed nations will soon have adequate supply, but must address hesitancy to increase demand

Urgency to get vaccine to Southern Hemisphere as winter approaches

Low- and middle-income countries lack vaccine supply; redistribution from developed nations is crucial to protect populations

Phased approach to reopening will save lives

A planned and phased approach to reopening alongside other public health measures is critical

COVID-19 will stay; goal to treat as "next flu"

COVID-19 will not be fully eliminated; the mid-term objective is to derisk and manage it like the "next flu"

A.1 Vaccine development in record time

Year

Safe and effective vaccines were developed, tested, and approved with unprecedented speed



timeline

development

Vaccine

Vaccine candidates

As of March 15th, 2021, 12¹ vaccine candidates have been approved for use globally

Registration trials have resulted in 0 hospitalizations and deaths



Process acceleration

Despite concerns, no steps were skipped in the vaccine development process

Regulatory agencies substantially accelerated review between phases

<12 month COVID-19 vaccine timeline



Looking ahead

Clinical assessments for approved vaccines will continue throughout vaccination rollout

Thus far, vaccines scrutinized by scientific community were found safe and effective

Both public health and private organizations continue to emphasize importance of vaccination and combating misinformation with education on vaccine safety and efficacy

1. CanSino Biologics, Sinovac, Gamaleya, WIBP Sinopharm, BIBP Sinopharm, Vektor, Pfizer BioNTech, Moderna, AstraZeneca, Bharat Biotech, CoviVac, Janssen; 2. Phased approvals are sequential approvals for specific segments of population based on Phase III results; 3. Emergency use authorization Source: FDA, CDC, Press search, BCG

A.2 Vaccination uptake will follow "S-curve"

Vaccine uptake can be modeled along a predictive path, shaped by shifting constraints and supply



Looking ahead

illustration

Conceptual

As nations continue to obtain more vaccine supply, they will reach an inflection point where demand will be the primary constraint. Priorities will shift from increasing vaccine supply to increasing uptake among different populations, particularly those that are vaccine hesitant





Note: Data counted as a single dose and may not equal the total number of people vaccinated, depending on the specific dose regime. For China and Russia, first available data point in December is treated as Day 0, although vaccinations commenced in Summer/Fall 2020 Source: Our World in Data

A.3 Vaccine effectiveness proven in real world

Israel is a successful example showing that broad vaccination across the population results in controlling cases

Key statistics

ata

Vaccination

- >50% of total population has received at least 1 dose (~4.5M people)
- >80% of people aged 60+ are fully vaccinated
- ~50% decrease in hospitalizations since peak¹





1. Change in 7-day trailing average of daily hospitalizations from Jan 21st peak to Mar 4th; 2. 7-day trailing average of daily hospitalizations in Israel; 3. Third lockdown ended on February 8, 2021; 4. People with severe allergic reactions, recovered patients, and <16 years are not yet eligible Source: Our World in Data; Israel Ministry of Health; MedRXIV; Jerusalem Post; Times of Israel; CNN

Looking ahead

Israel continues to vaccinate more people while continuing with other **public health measures**

Israel continues to promote vaccination while closely monitoring different **variants**

Reopening continues as vaccinated people are issued a "green pass", which can be presented on paper or via mobile

10

2021 Version 2.0

B.1 Developed nations must focus on uptake

Developed nations will soon have adequate supply, but must address hesitancy to increase demand

U.S. example shown

supply

Vaccine

hesitancy

Vaccine

"U.S. vaccine supply forecasts

Based on current manufacturer commitments, the U.S. will have enough vaccines available for:

- 200 million people in CDC's priority groups by early May¹
- All **250** million U.S. adults by end of May²



1. Captures all priority groups (~202M) including healthcare workers, 65+, health vulnerable, and essential workers since prioritization varies across states ; 2. 77% of US population (~253M) over 18 years old; 3. Excluding Black Americans and White Americas age 55 to 64. Note: Vaccine supply estimates based on US purchasing agreements, including for J&J vaccine, which was given Emergency Use Authorization by FDA late February; Assumes near constant flow of doses from manufacturer. Hesitancy is attributed to respondents who answered 'Maybe,' 'Somewhat unlikely,' or 'Highly unlikely' to a question asking whether they would make an appointment for a COVID-19 vaccine today if it were available; responses filtered to include only individuals who had not already received a vaccine and were not scheduled to receive a vaccine at the time of the survey.

Individuals who had not already received a vaccine and were not scheduled to receive a vaccine at the time of the survey. Source: BCG National Vaccine Sentiment Survey February 17-22, 2021; n = 1,450; overall sample representative of US adult population by age, income, ethnicity, gender, and region); US American Community Survey 2019; CDC COVID Data Tracker; New York Times; Bloomberg; NPR; Pfizer, Moderna, and J&J press releases

Looking ahead

Rapidly expand vaccine throughput **capacity** to accommodate for supply increases immediately

This includes building slack capacity into system to allow for uneven supply releases

Urgently address **vaccine hesitancy** through targeted outreach to increase uptake of vaccine

B.2 Urgent need to get vaccine to Southern Hemisphere as winter approaches

No data

0-5

5-10

10-50

Low- and middle-income countries¹ lack vaccine supply; redistribution from developed nations is crucial to protect populations

contracts

Vaccine

70%

of vaccines have gone to people representing **20%** of countries

These countries have an average GDP per capita more than 2x global average

50% of countries have only secured enough vaccine supply for 5% of

their population



% of population covered

As of 01 Mar 2021

Vaccine doses administered per 100 people

Looking ahead

Mission critical to protect populations in low- and middle-income countries as variants proliferate and winter approaches in the Southern Hemisphere

It is imperative to **redistribute vaccines** immediately from wealthy nations to prevent impending health crises

1.Low- and middle-income countries, defined as countries with a GNI per capita of <\$12,536 per year (World Bank) Source: Our World in Data; Bloomberg Vaccine Contract Tracker

B.3 Phased approach to reopening will save lives

A planned and phased approach to reopening alongside other public health measures is critical



Looking ahead

It is critical for businesses, schools, etc. to use a **phased reopening** approach, with clear thresholds for action based on local **infection dynamics** and **vaccination progress**

As reopening commences, COVID-19 testing, contact tracing, and other public health measures **should continue** to be upheld

by B(

B.4 COVID-19 will stay; goal to treat as "next flu"

COVID-19 will not be fully eliminated; the mid-term objective is to de-risk and manage it like the "next flu"



rates

Hospitalization

COVID-19 vaccines can help reduce hospitalization rates to **manageable levels** that are even **below** the hospitalization rates of the **annual flu**

Variants introduced over time pose risks to vaccine efficacy

As of 05 Mar 2021





Looking ahead

Through **regular vaccination**, COVID-19 risk can be managed to levels similar to those of the **annual flu**

Variants have the potential to **increase** COVID-19 infectiousness and/or **decrease** vaccine effectiveness

Booster shots administered on a regular cadence can help **combat variants**

1. Derived using the CDC's data on COVID-19 net hospitalization, South Korea's hospitalization data, and data from the New York City Department of Health and Mental Hygiene. Note: Several of the concerning variants (e.g., those first identified in the UK and South Africa), share mutations (e.g., N501Y), while also having distinct mutations (some more than others) Source: JAMA, Nextstrain, Financial Times, Virological, CDC, New York City Department of Health and Mental Hygiene, real world data in South Korea and Israel, BCG analysis

14

Vaccine roll-out underway amidst spread of COVID-19 variants; vaccine distribution and access raise ethical questions

As of 18 Mar 2021



President Biden says US would have enough vaccine doses for every adult American by the end of May



As COVID-19 vaccines spread, so do underhanded ways to get them—not everyone is prepared to wait their turn



Virus variant in Brazil infected many who had already recovered from COVID-19



U.K. to fast-track approval of vaccines for COVID-19 variants



Emmanuel Macron urges Europe and US to send 5% of vaccines to Africa



Hundreds of fake COVID-19 vaccines seized in South Africa, Interpol says



European nations will resume AstraZeneca vaccine rollout as EU regulator affirms safety



Texas and other states ease COVID-19 rules despite warnings

Action areas for leaders | Menu of actions under consideration by companies to encourage uptake among employees, subject to local regulation

ACTIONS FOR LEADERS

	Educate & encourage	Facilitate access	Incentivize	Penalize	Mandate
	Educate employees on vaccines and/or encourage uptake	Make it easier for employees to get vaccinated	Reward individuals for inoculating	Punish individuals for not inoculating	Require vaccination for a group of individuals
ample ventions	Encourage vaccination and highlight benefits through educational information; sharing science and	Adjust workers' schedules around vaccine appointments	Provide paid time off and transportation to vaccination Provide \$100 for vaccination	Restrict work travel or attendance at company events without vaccine	Mandate employees to be vaccinated
Ex inter	evidence from trusted authorities	Provide onsite vaccination	or educational course if medical/religious exemption	No paid medical leave if vaccine is refused	Require proof of vaccination for onsite vendors and/or customers
					More complex issues with

liability and legal issues to resolve, complex communications

Simpler interventions (minimal liability or legal issues, straightforward communications)

BCG Executive Perspectives

AGENDA

LESSONS LEARNED FROM THE FRONTLINE OF THE GLOBAL COVID-19 VACCINE ROLLOUT

Global vaccine development and implementation Equitable vaccine distribution and path to normality

UPDATED ANALYSES AND IMPACT

Epidemic progression and virus monitoring Economic and business impact

After a substantial case peak during Northern Hemisphere's winter, global case volumes have begun to drop

As of 15 Mar 2021



© 2021 by Bo:

EPIDEMIC

PROGRESSION

COVID-19 has broader geographic reach today with countries at different stages in their fight

As of 15 Mar 2021





Copyright © 2021 by Boston Consulting

March 2021 Version 2.0

Many large economies expected to continue recovery and reach 2019 GDP levels between 2021-2022

As of 01 Mar 2021

GDP forecast levels indexed to 2019 value (Base: 100)



Note: As of reports dated 08 June 2020 to 01 Mar 2021, YoY forecasts 2020 values are estimated actual GDP; 1. For India, forecast is for financial year; for other countries, the forecast is for calendar year; 2. Range from forecasts (where available) of JPMorgan Chase; Morgan Stanley; Bank of America; Fitch Solutions; Credit Suisse; Danske Bank; ING Group; HSBC; Source: Bloomberg; World Bank; IMF; BCG

ECONOMIC IMPACT

Retail and recreation mobility recovered fastest; public transit mobility remains lower in most countries

As of 01 Mar 2021

Workplace¹, public transit² and retail & recreation³ mobility compared to baseline of January 2020 to February 2020



1. Tracked as changes in visits to workplaces; 2. Tracked as changes in visits to public transport hubs, such as underground, bus and train stations; 3. Tracked as changes for restaurants, cafés, shopping centers, theme parks, museums, libraries and cinemas; 4. Refers to average lockdown start and easing dates; Note: Data taken as weekly average compared with baseline (average of all daily values of respective weeks during Feb 15 2020–Feb 28 2021); Source: Google LLC "Google COVID-19 Community Mobility Reports". https://www.google.com/covid19/mobility/ Accessed: 01 Mar 2020; Press search; BCG

ECONOMIC

IMPACT

Manufacturing PMI recovery globally indicates positive momentum

As of 01 Mar 2021

≤ -30%

Lockdown started

-29% to -15%

Manufacturing PMI before, during, and after the crisis

-14% to 0%

Lockdown easing

> 0%





Jan Feb Mar Apr May Jun July Aug Sep Oct Nov Dec Jan









South Korea





1. Lockdown dates are only pertaining to Hubei province; Note: PMI (Purchasing Manager's Index) is a diffusion index that summarizes whether market conditions, as viewed by purchasing managers, are expanding, staying the same, or contracting. 50 is neutral, >50 is considered to be positive sentiment and <50 is considered to be negative sentiment; Source: Markit South Korea Manufacturing PMI SA; Jibun Bank Japan Manufacturing PMI SA; China Manufacturing PMI SA; Swedbank Sweden PMI SA; Markit/BME Germany Manufacturing PMI SA; Markit Italy Manufacturing PMI SA; Markit US Manufacturing PMI SA; EIKON

Jan Feb

ed. BCG Executive Copyright © 2021 by Boston Consulting Grou 22

ed 19 March 2021 Version 2.0

ECONOMIC

IMPACT

Passenger vehicle sales see rebounds but dips again in countries with second wave of lockdowns

As of 01 Mar 2021

Monthly passenger vehicle¹ sales, YOY % change vs past year



1. Passenger vehicle sales includes data on, where available, hatchback, MPV, pickup, sedan, SUV, and vans; 2. Stimulus policies: Launched subsidies for car purchases in 10 cities, lessened purchase restriction in high tier cities and extended NEV subsidies; 3. South Korea's growth in auto sales from Mar through June 2020 is supported by recent tax cuts for individual consumption goods (e.g., cars), several carmakers (e.g. Audi, VW) launching new models and the increased appreciation by the Koreans of cars as a safe mode of transport and as a travel alternative for camping during COVID-19, supported by recently passed legislation to allow a variety of different cars to be modified into 'camping cars'. Source: Marklines; BCG

ECONOMIC

IMPACT

Retail goods sales (excl. auto and fuel) have rebounded to pre-COVID-19 levels across most countries

As of 15 Mar 2021

Growth of total retail goods sales (excl. auto & fuel)¹, YOY % change vs same month past year

Retail goods sales include online & offline sales and comprise food & beverages, apparel, cosmetics & personal care, home appliances, general merchandise, building material; do not include auto, fuel & food services

	Jan	Feb	Mar	Apr	Мау	June	July	Aug	Sep	Oct	Nov	Dec	Jan '21
US	4%	4%	1%	-15%	-4%	3%	4%	5%	7%	6%	5%	2%	10%
UK	1%	0%	-4%	-19%	-11%	1%	3%	4%	6%	7%	6%	-	-
Italy	1%	2%	-18%	-27%	-11%	-1%	-11%	1%	0%	1%	-7%	-6%	-8%
Sweden	3%	5%	2%	-3%	2%	3%	2%	2%	3%	3%	5%	0%	3%
Belgium	2%	1%	-6%	-14%	2%	7%	3%	14%	5%	8%	-5%	9%	5%
China ²	-10	5%	-12%	-6%	-1%	2%	-2%	-1%	2%	1%	4%	4%	-
Japan	0%	2%	1%	-6%	-2%	9%	7%	7%	-1%	12%	8%	6%	3%
≤ -30%	-2	29% to -15	5% -	14% to 0%	<mark>⁄0</mark>	> 0%							

1. Retail goods sales categorization may be different across countries; seasonally adjusted values taken; country-specific categorization; 2. For China, combined value of Jan & Feb is available Source: US Census Bureau; PRC National Bureau of Statistics; Eurostat; Ministry of Economy Japan Retail goods sales have **rebounded** to pre-COVID-19 levels, with countries showing higher growth levels than in Jan

ECONOMIC

IMPACT

US and UK have seen consistent retail sales growth over last 6 months

Some European countries have seen retail sales dips coinciding with second waves of cases/lockdown

24

De-averaged view | Retail store sales in China have rebounded across categories; apparel sales continue to be impacted in other countries

As of 15 Mar 2021

Retail store sales breakdown by category, YoY % change vs same month in past year

Food & beverage stores

	Мау	June	Jul	Aug	Sep	Oct	Nov	Dec	Jan '21
US	15%	12%	11%	10%	10%	10%	11%	9%	12%
UK	4%	4%	2%	2%	2%	2%	6%	-	-
Italy	1%	-1%	-2%	2%	1%	2%	3%	4%	3%
Sweden	0%	1%	0%	2%	3%	2%	2%	2%	0%
Belgium	10%	4%	4%	5%	2%	6%	2%	11%	4%
China ¹	11%	11%	7%	2%	5%	5%	9%	9%	-
Japan	2%	3%	1%	2%	2%	4%	0%	-1%	0%

Apparel stores²

	Мау	June	Jul	Aug	Sep	Oct	Nov	Dec	Jan '21		Мау	June	Jul	Aug	Sep	Oct	Nov
US	-62%	-24%	-23%	-20%	-9%	-11%	-16%	-16%	-10%	US	-42%	-20%	-6%	-4%	-7%	-5%	-10%
UK	-60%	-34%	-25%	-15%	-14%	-14%	-29%	-	-	UK	-29%	2%	12%	13%	11%	18%	21%
Italy	-43%	-18%	-41%	-2%	-3%	-4%	-44%	-26%	-40%	Italy	-15%	2%	0%	2%	2%	2%	-12%
Sweden	-31%	-22%	-22%	-18%	-14%	-14%	-25%	-30%	-24%	Sweden	15%	15%	15%	7%	10%	9%	17%
Belgium	-35%	-9%	-33%	18%	-7%	-14%	-73%	-13%	-	Belgium	2%	14%	2%	23%	19%	16%	-18%
China ¹	-1%	0%	-3%	2%	6%	10%	5%	4%	-	China ¹	4%	10%	-2%	4%	-3%	1%	5%
Japan	-35%	-6%	-19%	-18%	-24%	-4%	-8%	-5%	-18%	Japan	9%	26%	12%	10%	-29%	29%	25%

≤ -30% -29% to -15% -14% to 0% > 0%

y, for % change vs same month in pa

Personal care & cosmetics stores

	Мау	June	Jul	Aug	Sep	Oct	Nov	Dec	Jan '21
US	-8%	-1%	4%	4%	5%	4%	4%	5%	7%
UK	-30%	-5%	-1%	1%	15%	14%	3%	-	-
Italy	-13%	-9%	-5%	-1%	-2%	-2%	-2%	-12%	-13%
Sweden	-5%	3%	1%	2%	3%	0%	1%	0%	-3%
Belgium	-8%	0%	0%	3%	7%	9%	0%	-3%	-
China ¹	13%	21%	9%	22%	16%	20%	32%	9%	-
Japan	-3%	3%	1%	2%	-7%	3%	-1%	1%	-1%

Jan

'21

Dec

-16% -2%

-11% -1%

5% 11% 11% -

15% 11%

11%

Home appliance stores³

1. For China, Feb data includes both Jan & Feb, Food & beverages category only includes food & grains; 2. Includes clothing accessories, shoes, etc.; 3. Includes audio video & home appliances stores; Note: For US, share in retail store sales in Q4 2019: F&B ~25%, personal care & cosmetics ~12%, apparel ~6%, home appliances ~3%, general merchandising ~25% and building material & gardening equipment ~13%. Sector classification & mix may be different across countries; Source: US Census Bureau; PRC National Bureau of Statistics; Eurostat; Ministry of Economy Japan

ECONOMIC IMPACT

China's sales (except Home Appliances) have rebounded past year-ago run rates

Retail store sales recovery driven by **F&B** across all countries

Personal care & cosmetics category sales have rebounded to 2019 levels except in Italy

Apparel category saw the largest decline; continued fluctuations and far from recovery across countries except China

Home appliances sales with mixed development; US sales continue to struggle

25

Stock markets continue to have an optimistic outlook: 11 out of 24 sectors currently above pre-crisis TSR levels

TCD1

As of 01 Mar 2021

Utilities



Based on top S&P Global 1200 companies

	I	SK*
	21 Feb 2020 -20 Mar 2020	21 Feb 2020 -28 Feb 2021
Semiconductors	-30%	60%
Tech Hardware	-26%	25%
Media	-36%	21%
Materials	-32%	20%
Retailing	-40%	19%
Durable Goods	-39%	18%
Capital Goods	-35%	12%
Auto	-41%	12%
Financials	-35%	8%
Software	-30%	5%
Health Equipment	-31%	5%
Pharma	-20%	0%
Prof. Services	-30%	-1%
Household Products	-16%	-2%
Hospitality	-44%	-3%
Food/Staples retail	-10%	-3%
Insurance	-39%	-5%
Banks	-39%	-7%
Food & Beverage	-23%	-8%
Energy	-52%	-10%
Transport	-34%	-11%
Telecom	-17%	-13%
Real Estate	-39%	-13%

-30%

Companies² with probability of default >15%³

21 Feb 2020	28 Feb 2021
0%	0%
0%	0%
0%	0%
5%	4%
0%	18%
0%	0%
2%	2%
0%	0%
0%	0%
0%	0%
0%	0%
0%	5%
0%	0%
0%	0%
8%	15%
0%	0%
0%	0%
0%	4%
0%	0%
0%	12%
0%	24%
0%	4%
0%	0%
0%	3%

1. Performance is tracked for two periods, first from 21 February 2020 (before international acceleration of outbreak) to 20 March 2020 (trough of the market) and from 21 February 2020 through 28 Feb 2021; 2. Retailing, Hospitality, Transport and Energy are sectors with > 10% of companies with a probability of default > 15%; 3. Implied by 5-year credit default swap based on median; Note: Based on top S&P Global 1200 companies; Sectors are based on GICS definitions; Source: S&P Capital IQ; BCG ValueScience Center; BCG

-16%

Additional perspectives on COVID-19



US Vaccine sentiment



Seven lessons from the corporate frontlines



As vaccines roll out, testing still matters



Getting to the COVID-19 Finish Line: A Drama in 3 Acts



Why the global economy is recovering faster than expected



What 12,000 employees have to say about the future of remote work



Reimagining global health after the coronavirus



A Vaccination Strategy to Save Lives and Livelihoods



Designing resilience into global supply chains

Disclaimer

The services and materials provided by Boston Consulting Group (BCG) are subject to BCG's Standard Terms (a copy of which is available upon request) or such other agreement as may have been previously executed by BCG. BCG does not provide legal, accounting, or tax advice. The Client is responsible for obtaining independent advice concerning these matters. This advice may affect the guidance given by BCG. Further, BCG has made no undertaking to update these materials after the date hereof, notwithstanding that such information may become outdated or inaccurate.

The materials contained in this presentation are designed for the sole use by the board of directors or senior management of the Client and solely for the limited purposes described in the presentation. The materials shall not be copied or given to any person or entity other than the Client ("Third Party") without the prior written consent of BCG. These materials serve only as the focus for discussion; they are incomplete without the accompanying oral commentary and may not be relied on as a stand-alone document. Further, Third Parties may not, and it is unreasonable for any Third Party to, rely on these materials for any purpose whatsoever. To the fullest extent permitted by law (and except to the extent otherwise agreed in a signed writing by BCG), BCG shall have no liability whatsoever to any Third Party, and any Third Party hereby waives any rights and claims it may have at any time against BCG with regard to the services, this presentation, or other materials, including the accuracy or completeness thereof. Receipt and review of this document shall be deemed agreement with and consideration for the foregoing.

BCG does not provide fairness opinions or valuations of market transactions, and these materials should not be relied on or construed as such. Further, the financial evaluations, projected market and financial information, and conclusions contained in these materials are based upon standard valuation methodologies, are not definitive forecasts, and are not guaranteed by BCG. BCG has used public and/or confidential data and assumptions provided to BCG by the Client. BCG has not independently verified the data and assumptions used in these analyses. Changes in the underlying data or operating assumptions will clearly impact the analyses and conclusions.

The situation surrounding COVID-19 is dynamic and rapidly evolving, on a daily basis. Although we have taken great care prior to producing this presentation, it represents BCG's view at a particular point in time. This presentation is not intended to: (i) constitute medical or safety advice, nor be a substitute for the same; nor (ii) be seen as a formal endorsement or recommendation of a particular response. As such you are advised to make your own assessment as to the appropriate course of action to take, using this presentation as guidance. Please carefully consider local laws and guidance in your area, particularly the most recent advice issued by your local (and national) health authorities, before making any decision.

